Auradinescalability, sustainability and security solutions for the infrastructure, enabled by revolutionary blockchain, security, zero-knowledge and AI technologies.
Ascend supports manufacturing and process development projects from design through to clinical and commercial scales. They partner with biotechnology teams to embed scalable manufacturing in their operations from the beginning. They respond to customer inquiries by phone and contact form.
Auron Therapeutics is a biotechnology company based in Wellesley, Massachusetts, dedicated to developing innovative therapies for cancer. Founded in 2018, the company aims to transform the treatment paradigm by shifting from traditional cell-killing approaches to differentiation therapy, which seeks to convert malignant cells into normal functioning cells. This strategy reactivates the body's inherent cellular programs to promote tumor maturation and restore normal tissue. Auron Therapeutics utilizes advanced platforms that integrate large omic datasets with high-throughput flow cytometry, enabling the rapid identification and validation of multiple therapeutic targets and drugs using primary human patient samples. Through its research, the company aspires to address unmet medical needs in oncology and provide life-saving treatments for cancer patients.
They are developing a next-generation radioisotope power system that converts the heat from recycled nuclear waste into electricity.Their novel fuel and shielding design results in a system that is lightweight, cost-effective, and provides always-on, resilient power for years at a time.
Brimstone Energy is a hardware cleantech startup that aims to reduce CO2 emissions through innovative technologies.
Plotlogic Pty Ltd is a Brisbane-based company that specializes in developing advanced ore characterization systems for the mining industry. The firm employs hyperspectral imaging technology through its flagship product, OreSense LV, which identifies variations in a mine's geological model. Additionally, it offers OreBlocks, an API designed to enhance planning processes, and OreCheck, which provides real-time alerts regarding material variations. The technology aims to improve ore recovery and minimize dilution while also reducing carbon emissions and operational costs. Plotlogic's systems are applicable to various commodities, including coal, iron ore, and gold. Founded in 2005, the company is dedicated to offering customized support services alongside its innovative solutions.
Creyon Bio is a pre-clinical stage company focused on advancing drug development through a data-driven methodology. It specializes in engineering RNA-based medicines and their components by creating proprietary datasets that inform advanced machine learning models. This innovative approach enables the rapid identification of design rules and engineering principles necessary for the development of safe and effective oligonucleotide-based medicines. By leveraging these insights, Creyon Bio aims to improve the efficiency of the drug development process, ultimately contributing to cost savings in the healthcare sector while catering to diverse patient populations.
Amogy is a start-up, located in Brooklyn, New York and is working on a novel carbon-free energy storage system using ammonia as a fuel.
Petra is a Robotics company that focuses solely on underground utilities. Petra enables undergrounding critical utilities by boring utility tunnels through previously impenetrable geologies.
Developer of chemical biology technologies designed to create therapeutics for untreatable diseases. The company's technology uses the power of covalent bonding and a proprietary technology platform for high-throughput drug discovery, enabling pharmaceutical developers to convert genetic discoveries into real drugs to treat cancer, Alzheimer's, infectious diseases, and even aging.
Kettle Inc. is an innovative company based in Kensington, California, specializing in online risk analysis for the insurance industry. Founded in 2020, Kettle develops a machine-learning powered platform that utilizes deep learning algorithms to analyze over seven billion lines of satellite, weather, and ground truth data. By employing Swarm Neural Networks, the platform identifies patterns that enhance the accuracy of risk predictions related to climate change, thereby assisting insurers in managing catastrophic risks. Kettle's approach aims to improve underwriting processes and reduce loss ratios, enabling the sale of reinsurance to other insurers while effectively balancing risk in an evolving climate landscape.
CH4 Global Inc. is a holding company based in San Francisco, California, that specializes in producing seaweed bio-products aimed at reducing methane emissions from livestock. Founded in 2019, the company focuses on Asparagopsis armata, a seaweed supplement that has been scientifically proven to decrease methane emissions from ruminant animals such as cows, goats, sheep, and deer by up to 90%. By leveraging advanced aquaculture techniques, CH4 Global provides innovative solutions to mitigate greenhouse gases on a global scale, with its products offered through subsidiaries in the United States, Australia, New Zealand, and the Pacific. The company has attracted investment from family offices and private investors, as well as support from government organizations, to further its mission of addressing climate change while providing benefits like carbon credits for farmers and food producers.
GenEdit Inc. is a biotechnology company based in Berkeley, California, established in 2016. It specializes in developing innovative genome editing technologies, particularly using the CRISPR/Cas9 system for therapeutic gene editing. The company focuses on addressing the challenges associated with the delivery of gene therapies through its proprietary non-viral nanoparticle-based delivery platform. This platform enables more efficient and accurate delivery of CRISPR components, enhancing the potential for curative treatments for genetic diseases. By systematically screening a library of nanoparticles, GenEdit aims to improve the safety and effectiveness of gene editing, making it a promising solution for a wide range of therapeutic applications.
Stemson Therapeutics, LLC operates as a cell therapy company that helps to restore natural hair. The company produces cells required to regenerate hair follicles using the novel cell engineering process. Its products include the stemson solution, a solution that generates novo follicles using induced pluripotent stem cells (iPSC) to grow new Dermal Papilla. The company was founded in 2018 and is based in LA Jolla, California.
Twelve, formerly known as Opus 12, is a Berkeley, California-based company that specializes in recycling carbon dioxide emissions into valuable chemicals and fuels. Founded in 2015, the company has developed innovative technology that can be integrated with any source of CO₂ emissions. By utilizing only water and electricity as inputs, Twelve transforms captured carbon dioxide into essential products such as methane, ethylene, and ethanol. The firm aims to provide a cost-competitive alternative to petroleum-derived chemicals and fuels, thereby addressing carbon emissions while simultaneously creating economically viable solutions.
BioPhero ApS provides bio-based pheromones for pest management. The company was founded in 2016 and is based in Kongens Lyngby, Denmark.
Plexium, Inc. is a biotechnology company based in San Diego, California, established in 2017. The company specializes in drug development, focusing on the identification of small molecules that modulate E3 ligases for therapeutic applications in cancer and neurodegenerative diseases. Plexium employs a DNA-encoded library platform to conduct high-throughput screening, utilizing cell-based assays to discover molecular glues that can alter E3 ligase substrate recognition, thereby inducing, inhibiting, or modulating protein degradation. This innovative approach allows Plexium to selectively target various cancers, including small cell lung and breast tumors, while also exploring mechanisms to enhance immune responses through E3 ligase modulation.
Deepcell, Inc. is a company based in Mountain View, California, focused on advancing diagnostic technologies through a non-invasive approach. Founded in 2015, it has developed a microfluidic imaging platform that leverages artificial intelligence to classify cells by their visual features. This technology allows for the isolation of viable cells based on their morphological characteristics, facilitating detailed genetic health assessments from standard blood samples. By enabling insights at the single-cell level, Deepcell aims to improve the diagnosis and treatment of various diseases, offering researchers a valuable alternative to invasive diagnostic methods.
Subtle Medical, Inc., a healthcare technology company, develops medical imaging software for clinical imaging centers and hospitals. Its product includes SubtleMR, an artificial intelligence-based image processing software that reduces image noise and increases image sharpness for non-contrast enhanced magnetic resonance imaging (MRI). It enables to reduce cost, imaging time, and radiation/contrast dose. The company was founded in 2017 and is based in Menlo Park, California.
Provider of immunotherapies intended to transform cancer treatment and improve quality of life. The company's cellular immunotherapy platform uses gene therapy to target cancer cells and delivers to any patient, with any tumor, at any time to directly, safely, and controllably attack cancer, enabling medical practitioners to safeguard patients by creating and harnessing a powerful immune response in the body.
Provider of immunotherapies intended to transform cancer treatment and improve quality of life. The company's cellular immunotherapy platform uses gene therapy to target cancer cells and delivers to any patient, with any tumor, at any time to directly, safely, and controllably attack cancer, enabling medical practitioners to safeguard patients by creating and harnessing a powerful immune response in the body.
Unlearn is a San Francisco-based company founded in 2017 that specializes in using artificial intelligence to enhance clinical research. It develops innovative software tools aimed at improving clinical trial design, including the creation of Digital Twins to generate Intelligent Control Arms. By utilizing historical datasets and disease-specific machine-learning models, Unlearn produces virtual placebo patients derived from actual patient baseline data, which helps to increase trial power, accelerate timelines, and provide patient-level insights. This approach reduces or eliminates the need for concurrent control arms in clinical studies, streamlining the research process. Unlearn has garnered significant attention, securing $20 million in funding and collaborating with leading pharmaceutical companies. Its work has been recognized in prestigious publications, including a peer-reviewed article in Nature, and it has been acknowledged as a key player in digital health innovation. The company continues to engage with regulators and industry leaders to drive advancements in clinical research through the application of AI technologies.
Alchemab Therapeutics is developing natural protective antibodies designed to keep people free of hard-to-treat diseases. They are building their transformative engine to identify novel drug targets and develop a broad pipeline of novel antibody therapeutics for hard-to-treat cancers, neurodegenerative conditions, and infectious diseases.
Golden is a developer of a self-constructing knowledge database used to accelerate discovery and education. The company uses and leverages human effort by using machine intelligence to make the process of gathering and communicating knowledge simpler. It combines a powerful search across several entities with fine-grain alerts to stay on top of changes, and semi-automatic research assistance for gaps in knowledge that enable people in organizations to stay current, understand and leverage the latest trends in their industry.
Auransa is an AI-driven platform for discovering drugs of novel pharmacology from vast amounts of genomics data collected from human disease tissues. The company's platform is used to study molecular disease subtypes and predict compounds and targets for responder patient population. Current internal drug pipeline includes cancer and other diseases. The company has partnership with companies and institutions in biopharma industry.
Proprio, Inc. is a Seattle-based healthcare technology company founded in 2016, specializing in next-generation surgical navigation and imaging solutions. The company develops a platform that integrates machine learning, automated intelligence, and mixed-reality user interfaces to enhance surgical accuracy and streamline workflows. By utilizing advanced technologies such as light field computer vision and depth-sensing capabilities, Proprio's system replaces traditional surgical microscopes, navigation systems, and loupes, offering a more immersive 3D environment for medical professionals. This innovative approach aims to improve patient outcomes while allowing for greater adaptability in surgical practices. Proprio's vision extends beyond mere technological upgrades; the company seeks to revolutionize the medical field by harnessing software development techniques, thereby enabling rapid innovation and a more integrated use of data and artificial intelligence in surgery.
Unlearn is a San Francisco-based company founded in 2017 that specializes in using artificial intelligence to enhance clinical research. It develops innovative software tools aimed at improving clinical trial design, including the creation of Digital Twins to generate Intelligent Control Arms. By utilizing historical datasets and disease-specific machine-learning models, Unlearn produces virtual placebo patients derived from actual patient baseline data, which helps to increase trial power, accelerate timelines, and provide patient-level insights. This approach reduces or eliminates the need for concurrent control arms in clinical studies, streamlining the research process. Unlearn has garnered significant attention, securing $20 million in funding and collaborating with leading pharmaceutical companies. Its work has been recognized in prestigious publications, including a peer-reviewed article in Nature, and it has been acknowledged as a key player in digital health innovation. The company continues to engage with regulators and industry leaders to drive advancements in clinical research through the application of AI technologies.
AbCellera Biologics Inc. is a biotechnology company that specializes in the discovery and development of therapeutic antibodies. Founded in 2012 and headquartered in Vancouver, Canada, it has created a full-stack, AI-powered platform that analyzes natural immune systems to identify antibodies suitable for drug development. The company employs next-generation transgenic mice, which generate fully human antibodies, enhancing its ability to discover effective therapeutic candidates. AbCellera's innovative approach addresses the limitations of traditional antibody discovery by enabling faster and more precise identification of optimal clinical candidates. It has established partnerships with various pharmaceutical companies, including a significant collaboration with Eli Lilly and Company to explore multiple targets. Through its proprietary technologies and expertise, AbCellera aims to streamline the antibody discovery process and support the development of next-generation therapeutics.
Culture Biosciences, founded in 2016 and headquartered in San Francisco, California, specializes in developing automated bioreactors and tools for fermentation. The company provides a digital bio-manufacturing platform that allows biotech companies to optimize their manufacturing processes, enabling them to bring products to market more efficiently. By utilizing robotic sample handling and cloud-based data monitoring and analysis, Culture Biosciences helps scientists run, monitor, and analyze bioreactors more quickly than traditional methods. This innovative approach supports the biotechnology sector in enhancing productivity and streamlining workflows.
C16 Biosciences, founded in 2017 and based in New York, specializes in developing sustainable alternatives to palm oil through microbial fermentation. The company addresses the environmental concerns associated with traditional palm oil production, which often involves deforestation and unethical labor practices. By using established fermentation processes, C16 Biosciences aims to provide food manufacturers, refiners, traders, and consumers with bio-based oils that reduce the ecological impact of palm oil. Their innovative approach allows producers to invest in sustainable practices, ultimately protecting natural resources and wildlife. C16 Biosciences' mission is to create a world where consumers can enjoy their favorite products without contributing to harmful environmental practices.
MycoWorks LLC specializes in the research, design, and manufacturing of sustainable leather alternatives derived from natural mycelium. Established in 2013 and based in San Francisco, the company produces a proprietary material called Reishi, which is water-resistant and customizable in texture and features. Reishi is designed to mimic the performance and feel of traditional leather while being animal-free and environmentally friendly. MycoWorks employs a unique platform known as Fine Mycelium to create this innovative biomaterial, which boasts qualities such as strength, durability, and biodegradability. The company aims to provide natural alternatives to conventional materials like plastic foams, textiles, and leather, catering to industries such as aerospace, automotive, apparel, and architectural interiors. Through its carbon-negative production process, MycoWorks offers a rapidly grown solution that aligns with sustainable design principles.
MycoWorks LLC specializes in the research, design, and manufacturing of sustainable leather alternatives derived from natural mycelium. Established in 2013 and based in San Francisco, the company produces a proprietary material called Reishi, which is water-resistant and customizable in texture and features. Reishi is designed to mimic the performance and feel of traditional leather while being animal-free and environmentally friendly. MycoWorks employs a unique platform known as Fine Mycelium to create this innovative biomaterial, which boasts qualities such as strength, durability, and biodegradability. The company aims to provide natural alternatives to conventional materials like plastic foams, textiles, and leather, catering to industries such as aerospace, automotive, apparel, and architectural interiors. Through its carbon-negative production process, MycoWorks offers a rapidly grown solution that aligns with sustainable design principles.
Advano, operating under NanoStar, Inc., is a New Orleans-based company specializing in silicon nanotechnology. Founded in 2014, Advano develops and produces functionalized silicon nanoparticles and quantum dots for various applications. Notably, its products enhance the energy density of lithium-ion batteries by 30-40%, making them suitable for electric vehicles, consumer electronics, and IoT devices, all without compromising battery life or increasing costs. Additionally, Advano's technology is applied in CO2 carbon capture, super hydrophobic coatings, and printable electronics, serving industries such as telecommunications.
Empirico is a company focused on developing an insights platform that leverages biological insights derived from human genetics to create new medicines. Its platform utilizes biological datasets and programmable biology to facilitate target discovery and development. This enables scientists to systematically generate, examine, and prioritize high-confidence therapeutic hypotheses, ultimately advancing the field of drug development through innovative approaches grounded in human genetic research.
Novome Biotechnologies, Inc. is a biotechnology company based in South San Francisco, California, that specializes in engineering bacteria from the human gut to address chronic diseases. Founded in 2015, the company has developed a platform for the controlled colonization of the gut with genetically engineered bacteria, known as Genetically Engineered Microbial Medicines (GEMMs). This innovative approach allows for sustained therapeutic interventions through the precise delivery of microbial activities. Novome's lead preclinical program targets hyperoxaluria by creating a therapeutic strain of bacteria aimed at degrading oxalate to help prevent kidney stone formation. The company is also expanding its synthetic biology platform to explore additional therapeutic applications.
Novome Biotechnologies, Inc. is a biotechnology company based in South San Francisco, California, that specializes in engineering bacteria from the human gut to address chronic diseases. Founded in 2015, the company has developed a platform for the controlled colonization of the gut with genetically engineered bacteria, known as Genetically Engineered Microbial Medicines (GEMMs). This innovative approach allows for sustained therapeutic interventions through the precise delivery of microbial activities. Novome's lead preclinical program targets hyperoxaluria by creating a therapeutic strain of bacteria aimed at degrading oxalate to help prevent kidney stone formation. The company is also expanding its synthetic biology platform to explore additional therapeutic applications.
Novomer is a materials company focused on developing high-performance, eco-friendly plastics, polymers, and chemicals. Established in 2004 and based in Waltham, Massachusetts, the company leverages proprietary catalytic technology to convert carbon dioxide and other renewable materials into cost-effective industrial products. This innovative approach combines traditional chemical feedstocks with carbon, enabling the sustainable synthesis of a range of chemicals and materials. Novomer’s technology not only offers competitive pricing but also contributes to environmental sustainability by addressing global warming and climate change challenges through the use of carbon in industrial applications.
Empirico is a company focused on developing an insights platform that leverages biological insights derived from human genetics to create new medicines. Its platform utilizes biological datasets and programmable biology to facilitate target discovery and development. This enables scientists to systematically generate, examine, and prioritize high-confidence therapeutic hypotheses, ultimately advancing the field of drug development through innovative approaches grounded in human genetic research.
X-37, LLC is a pharmaceutical discovery and development company based in South San Francisco, California, established in 2018. The company specializes in developing treatments for cancer, autoimmune diseases, and coagulation disorders. Utilizing advanced artificial intelligence technology from Atomwise, X-37 aims to discover novel drug candidates by screening extensive libraries of chemical compounds against significant pharmaceutical targets. This innovative approach enables the healthcare sector to expedite the discovery and development of new medicines, ultimately benefiting patients in need of effective therapies.
X-37, LLC is a pharmaceutical discovery and development company based in South San Francisco, California, established in 2018. The company specializes in developing treatments for cancer, autoimmune diseases, and coagulation disorders. Utilizing advanced artificial intelligence technology from Atomwise, X-37 aims to discover novel drug candidates by screening extensive libraries of chemical compounds against significant pharmaceutical targets. This innovative approach enables the healthcare sector to expedite the discovery and development of new medicines, ultimately benefiting patients in need of effective therapies.
Plexium, Inc. is a biotechnology company based in San Diego, California, established in 2017. The company specializes in drug development, focusing on the identification of small molecules that modulate E3 ligases for therapeutic applications in cancer and neurodegenerative diseases. Plexium employs a DNA-encoded library platform to conduct high-throughput screening, utilizing cell-based assays to discover molecular glues that can alter E3 ligase substrate recognition, thereby inducing, inhibiting, or modulating protein degradation. This innovative approach allows Plexium to selectively target various cancers, including small cell lung and breast tumors, while also exploring mechanisms to enhance immune responses through E3 ligase modulation.
Frontier Medicines Corporation is a pre-clinical stage biopharmaceutical company based in South San Francisco, California, founded in 2018. The company specializes in discovering and developing medicines that target cancer-causing proteins through its innovative chemoproteomics platform. This platform utilizes advanced computational techniques and machine learning to identify new binding pockets on proteins, thereby facilitating the discovery and development of small-molecule drugs. By enhancing the drug development process, Frontier Medicines aims to deliver breakthrough therapies that can significantly change the treatment landscape for debilitating diseases.
Frontier Medicines Corporation is a pre-clinical stage biopharmaceutical company based in South San Francisco, California, founded in 2018. The company specializes in discovering and developing medicines that target cancer-causing proteins through its innovative chemoproteomics platform. This platform utilizes advanced computational techniques and machine learning to identify new binding pockets on proteins, thereby facilitating the discovery and development of small-molecule drugs. By enhancing the drug development process, Frontier Medicines aims to deliver breakthrough therapies that can significantly change the treatment landscape for debilitating diseases.
Pickle Robots is a low cost, collaborative package handling robot that automates several key tasks along the e-commerce supply chain. Package handling is a physically demanding job with extremely high rates of turnover. The rising costs of shipping, comprised of 2/3rds labor, have become a major bottleneck to continued growth in e-commerce. Dill is the first robot from the Pickle Robot Company. It works multiple shifts, communicates with its human collaborators, and is rapidly developing new skills in handling e-commerce parcels: such as loading/unloading of feeder trucks, palletizing/depalletizing, and preloading of last mile delivery vans, trucks, and parcel cars.
Plexium, Inc. is a biotechnology company based in San Diego, California, established in 2017. The company specializes in drug development, focusing on the identification of small molecules that modulate E3 ligases for therapeutic applications in cancer and neurodegenerative diseases. Plexium employs a DNA-encoded library platform to conduct high-throughput screening, utilizing cell-based assays to discover molecular glues that can alter E3 ligase substrate recognition, thereby inducing, inhibiting, or modulating protein degradation. This innovative approach allows Plexium to selectively target various cancers, including small cell lung and breast tumors, while also exploring mechanisms to enhance immune responses through E3 ligase modulation.
Sickbay, developed by Medical Informatics Corp., is a software platform designed to enhance patient monitoring and analytics in healthcare settings. It archives, aggregates, and transforms high-resolution waveform data from various medical devices, enabling real-time access and analysis of patient information. The platform supports continuous data collection and employs machine learning and artificial intelligence to deliver predictive analytics that facilitate data-driven medicine and patient-centered care. Sickbay also addresses alarm management by reducing alarm noise and ensuring that relevant alerts reach care providers. This comprehensive approach assists doctors, nurses, hospital administrators, and medical researchers in making informed decisions to improve patient outcomes. Founded in 2010 and headquartered in Houston, Texas, Medical Informatics Corp. aims to provide innovative solutions that enhance the efficiency and effectiveness of healthcare delivery.
HelloVerify is a background screening platform designed to provide credible information on individuals, addressing the growing need for effective fraud prevention. By leveraging technology, HelloVerify offers a cost-effective and efficient solution for background checks, automating data collection and streamlining the process from order requests to final report delivery. The platform facilitates the verification of an individual's identity, court case status, educational background, credit score, and employment history, which is essential for making informed commercial transactions and hiring decisions. Its services cater to a diverse clientele, including corporations, startups, homeowners, and landlords, enabling them to authenticate applicants and assess their reliability efficiently. With a commitment to quick turnaround times and affordability, HelloVerify empowers users to establish trust and safety in their interactions.
Pachyderm, Inc. is a software company that specializes in developing a data engineering platform for managing complex, multi-stage data pipelines. Founded in 2014 and based in San Francisco, California, Pachyderm's platform facilitates the automation of data processes while ensuring reproducibility and data lineage throughout the machine learning development lifecycle. It offers a unique architecture that supports version control for data, allowing users to build scalable and language-agnostic machine learning and ETL workflows. The company's solutions include a free open-source version, an enterprise version, and a hub version, providing flexibility for users to choose the best fit for their needs. By enabling automatic scaling and parallel processing, Pachyderm empowers data science teams to work with any language, framework, or tool, making it an effective choice for sophisticated data transformations.
Empirico is a company focused on developing an insights platform that leverages biological insights derived from human genetics to create new medicines. Its platform utilizes biological datasets and programmable biology to facilitate target discovery and development. This enables scientists to systematically generate, examine, and prioritize high-confidence therapeutic hypotheses, ultimately advancing the field of drug development through innovative approaches grounded in human genetic research.
Founded out of MIT, Reach Labs is deeply rooted in technology and design. Their mission is to empower the world with seamless connectivity.
Empirico is a company focused on developing an insights platform that leverages biological insights derived from human genetics to create new medicines. Its platform utilizes biological datasets and programmable biology to facilitate target discovery and development. This enables scientists to systematically generate, examine, and prioritize high-confidence therapeutic hypotheses, ultimately advancing the field of drug development through innovative approaches grounded in human genetic research.
AbCellera Biologics Inc. is a biotechnology company that specializes in the discovery and development of therapeutic antibodies. Founded in 2012 and headquartered in Vancouver, Canada, it has created a full-stack, AI-powered platform that analyzes natural immune systems to identify antibodies suitable for drug development. The company employs next-generation transgenic mice, which generate fully human antibodies, enhancing its ability to discover effective therapeutic candidates. AbCellera's innovative approach addresses the limitations of traditional antibody discovery by enabling faster and more precise identification of optimal clinical candidates. It has established partnerships with various pharmaceutical companies, including a significant collaboration with Eli Lilly and Company to explore multiple targets. Through its proprietary technologies and expertise, AbCellera aims to streamline the antibody discovery process and support the development of next-generation therapeutics.
AbCellera Biologics Inc. is a biotechnology company that specializes in the discovery and development of therapeutic antibodies. Founded in 2012 and headquartered in Vancouver, Canada, it has created a full-stack, AI-powered platform that analyzes natural immune systems to identify antibodies suitable for drug development. The company employs next-generation transgenic mice, which generate fully human antibodies, enhancing its ability to discover effective therapeutic candidates. AbCellera's innovative approach addresses the limitations of traditional antibody discovery by enabling faster and more precise identification of optimal clinical candidates. It has established partnerships with various pharmaceutical companies, including a significant collaboration with Eli Lilly and Company to explore multiple targets. Through its proprietary technologies and expertise, AbCellera aims to streamline the antibody discovery process and support the development of next-generation therapeutics.
Interana Inc. is a company that specializes in developing a behavioral discovery and analysis platform. This platform allows users to investigate digital behavior, enabling data analysts and product managers to enhance onboarding experiences and feature utilization. Founded in 2013 and headquartered in Redwood City, California, Interana also has locations in Dallas, Texas, and Bellevue, Washington. The company's technology is designed to analyze vast amounts of data quickly, helping organizations understand customer behavior and product usage effectively.
Halter Limited, founded in 2016 and based in Morrinsville, New Zealand, specializes in advanced agricultural technology. The company designs GPS-enabled, solar-powered collars for cows, allowing farmers to monitor and manage their herds more efficiently. Utilizing a simple tablet application, farmers can remotely establish geographic boundaries, creating virtual fences to guide their animals without physical herding. Halter's system not only enhances productivity but also collects behavioral data to alert farmers about critical events, such as when cows are in heat, lame, or nearing calving. By optimizing herd management, Halter aims to modernize dairy farming practices and improve animal welfare.
GitPrime, Inc. is a developer productivity software company founded in 2015 and headquartered in Durango, Colorado. The company specializes in aggregating data from Git repositories, ticketing systems, and pull requests to generate clear insights and reports. GitPrime's platform enables engineering organizations to align their initiatives with desired outcomes and confidently adjust their processes. As of May 2019, GitPrime operates as a subsidiary of Pluralsight, Inc.
ENOUGH, formerly known as 3fbio Ltd., is a technology spin-out from the University of Strathclyde, established to develop and commercialize innovative patented technology for the production of mycoprotein, a meat-free food product. The company employs integrated fermentation processes that combine the production of mycoprotein with existing bio-refinery operations, which also generate bioethanol and animal feed as co-products. By utilizing glucose syrup as feedstock for mycoprotein and carbohydrate feedstock for bioethanol, ENOUGH aims to enhance production economics while promoting sustainable food solutions. Incorporated in 2015 and based in Glasgow, United Kingdom, the company focuses on transforming the food, fuel, and feed sectors through its advanced production methods.
Swift Medical Inc. is a Toronto-based company that specializes in wound care management through its mobile application, Swift. This application enables healthcare professionals to measure and document the progression of patients' wounds efficiently. By facilitating real-time sharing of wound images, Swift enhances communication among medical teams and ensures precise and consistent documentation. The platform is designed to provide comprehensive wound care solutions for healthcare enterprises, streamlining the process from initial assessment to ongoing treatment.
Fortem Technologies, Inc. is a company specializing in airspace security and safety solutions, focusing on intrusion detection and detect-and-avoid technology for drones and unmanned aerial vehicles (UAVs). Founded in 2016 and based in Provo, Utah, the company offers a range of products, including advanced radars like the DAA-R10 and DAA-R20, which provide crucial detection capabilities for aircraft integrators. Its ThreatAware AI analysis engine processes data from multiple sensors in real-time, enhancing situational awareness. Fortem also produces the F700 Patriot drone platform and the military-tested DroneHunter, designed for perimeter intrusion detection and protection. The company is privately held and backed by various investors, aiming to enable safe autonomous operations and facilitate unmanned aircraft operations beyond visual line of sight.
Atomwise, Inc. specializes in deep learning artificial intelligence technology aimed at small molecule drug discovery. The company leverages its proprietary AI platform, AtomNet, which contains over 16 billion molecules for virtual screening, to enhance the speed and accuracy of drug discovery processes. This technology employs a statistical approach to predict the binding of small molecules to proteins, aiding in drug hit discovery, binding affinity prediction, and toxicity detection. Atomwise collaborates on numerous projects each year with major pharmaceutical and agrochemical companies, as well as over 200 universities and hospitals across 40 countries. Founded in 2012 and based in San Francisco, Atomwise was previously known as Chematria, Inc. before rebranding in 2015.
Nyriad Limited is a technology company that specializes in advanced storage solutions tailored for big data and high-performance computing. Established in 2015 and based in Cambridge, New Zealand, Nyriad develops innovative products such as NSULATE, an ultra-fast erasure coding solution; NPAC, which offers parallel accelerated compression for real-time storage and network traffic; and NAPPA, a framework that integrates various compression and encoding codecs into server and client applications. The company’s compression technology platform leverages graphics processing units (GPUs) to deliver resilient data storage, addressing the scale, security, efficiency, and performance requirements of demanding IT projects. Nyriad's offerings support both storage and computing performance, catering to the needs of systems integrators and organizations engaged in high-performance data-driven initiatives.
Evonetix Ltd is a biotechnology company based in Little Chesterford, United Kingdom, established in 2015. The company focuses on developing innovative technology for the parallel synthesis of DNA on silicon arrays, thereby advancing the field of synthetic biology. By employing novel techniques, Evonetix aims to synthesize DNA with higher accuracy and scale, which enhances accessibility for researchers. This platform enables scientists to utilize synthetic biology on a previously unattainable scale, fundamentally changing how DNA is accessed, produced, and utilized for gene synthesis. The engineering team at Evonetix boasts extensive experience in creating high-integrity automated systems, bringing together a diverse range of expertise from various scientific and engineering disciplines to support its mission.
Interana Inc. is a company that specializes in developing a behavioral discovery and analysis platform. This platform allows users to investigate digital behavior, enabling data analysts and product managers to enhance onboarding experiences and feature utilization. Founded in 2013 and headquartered in Redwood City, California, Interana also has locations in Dallas, Texas, and Bellevue, Washington. The company's technology is designed to analyze vast amounts of data quickly, helping organizations understand customer behavior and product usage effectively.
nTopology, Inc. develops engineering design software that enhances manufacturing processes. Its primary offering, nTopology, allows engineers to create lightweight and optimized parts tailored to functional requirements. The software integrates design, simulation, and advanced manufacturing into a cohesive workflow, addressing geometry bottlenecks and enhancing team collaboration. Key features include Lightweighting, Architected Materials, Topology Optimization, Additive Manufacturing, and Design Analysis. nTopology's tools enable precise control over spatial variations, facilitating a broader range of designs and effective utilization of analysis data. The company serves various industries, including aerospace and defense, medical, automotive, consumer products, and education. Founded in 2013 and based in New York, nTopology aims to redefine engineering design tools for advanced manufacturing.
TigerGraph is a provider of a graph database platform for enterprise applications. It fulfills the true promise and benefits of the graph platform by supporting real-time deep link analytics for enterprises with complex and colossal amounts of data. TigerGraph’s proven technology is used by customers including Alipay, VISA, SoftBank, State Grid Corporation of China, Wish and Elementum. The company supports applications such as IoT, AI, and machine learning to make sense of ever-changing big data. It also provides personalized recommendations, fraud prevention, supply-chain logistics, company knowledge graph, and other features. Founded by Yu Xu, Ph.D. in 2012, TigerGraph is funded by Qiming VC, Baidu, Ant Financial, AME Cloud, Morado Ventures, Zod Nazem, Danhua Capital, and DCVC. TigerGraph is based in Redwood City, CA.
Cofactor Genomics is a biotechnology company focused on advancing precision medicine through predictive immune modeling. By leveraging its expertise in RNA sequencing and expression analysis, Cofactor aims to move beyond traditional single-analyte biomarkers to develop multidimensional biomarkers that enhance clinical insights. The company's platform examines RNA biomarkers linked to responses to targeted therapeutics, allowing biotechnology firms to create clinical diagnostic assays for oncology, immunology, and neurodegenerative diseases. With a CAP-certified clinical RNA sequencing laboratory and a suite of molecular, informatic, and database tools, Cofactor supports its partners in conducting more efficient and successful clinical trials, ultimately facilitating the commercialization of innovative therapeutic solutions.
Cofactor Genomics is a biotechnology company focused on advancing precision medicine through predictive immune modeling. By leveraging its expertise in RNA sequencing and expression analysis, Cofactor aims to move beyond traditional single-analyte biomarkers to develop multidimensional biomarkers that enhance clinical insights. The company's platform examines RNA biomarkers linked to responses to targeted therapeutics, allowing biotechnology firms to create clinical diagnostic assays for oncology, immunology, and neurodegenerative diseases. With a CAP-certified clinical RNA sequencing laboratory and a suite of molecular, informatic, and database tools, Cofactor supports its partners in conducting more efficient and successful clinical trials, ultimately facilitating the commercialization of innovative therapeutic solutions.
Freenome, Inc., is an artificial intelligence (AI) genomics biotech company. The company develops and provides a medical arti?cial intelligence platform for early detection of cancer. It develops blood tests for early-cancer screening and treatment selection. The company also provides clinical research services. Freenome, Inc. was founded in 2014 and is based in South San Francisco, California.
Karius, Inc. is a life sciences company dedicated to generating genomic insights for infectious diseases. It offers the Karius Test, a non-invasive blood test that utilizes sequencing of microbial cell-free DNA to identify and quantify various pathogens, including bacteria, DNA viruses, fungi, and parasites. This test is particularly useful for diagnosing complicated pneumonia, infections in immunocompromised patients, and endocarditis. Karius also provides laboratory services for pathogen biomarker detection tailored for biopharmaceutical companies. Founded in 2014, the company is based in Redwood City, California, with an additional office in Menlo Park. Its laboratory holds CLIA certification and CAP accreditation, allowing it to conduct high-complexity clinical laboratory testing to support rapid clinical decision-making.
Gro Intelligence is a data analytics platform focused on the global agriculture industry, utilizing artificial intelligence and machine learning to analyze a wide range of agricultural data. Founded in 2014 and headquartered in New York, with an additional office in Nairobi, the company aggregates and processes both structured and unstructured data from diverse sources, including satellite imagery and trade reports. By employing proprietary algorithms, Gro Intelligence generates predictive models that provide insights into weather patterns, trade flows, pricing dynamics, and production metrics. This enables financial institutions, corporations, and public sector entities to make informed decisions based on comprehensive and timely information. The company has attracted significant investment, raising $20 million to date from notable investors. With approximately 50 employees, Gro Intelligence aims to bridge data gaps within the agricultural sector, enhancing productivity and access to capital for stakeholders across the ecosystem.
Insight Engines, Inc. is a cybersecurity company that specializes in natural language understanding to enhance data investigation and threat detection. Founded in 2015 and based in San Francisco, the company offers its flagship product, Insight Engines Cyber Security Investigator, designed for integration with Splunk. This tool allows security teams to conduct investigations using plain English, significantly reducing the time required to identify and analyze cyber threats. Insight Engines serves a diverse clientele, including healthcare providers, financial institutions, and security software vendors, enabling them to efficiently navigate and leverage their log data. By providing timely recommendations and insights, the platform empowers organizations to perform technical investigations that would traditionally take much longer, thus improving their overall cybersecurity posture. Insight Engines operates as a subsidiary of Mr Buzz Inc, LLC.
Embark Trucks Inc. develops self-driving truck technology and highway autopilot system for commercial trucking. It designs artificial intelligence software that helps on long haul stretches in the trucking industry. Embark Trucks Inc. was formerly known as Varden Labs Inc. The company was founded in 2015 and is based in San Francisco, California.
Buoyant, Inc. is a technology company based in San Francisco, California, founded in 2015 by former Twitter infrastructure engineers. The company specializes in developing open-source software, particularly through its flagship product, Linkerd, which is an open-source network proxy designed to function as a service mesh. A service mesh enables efficient management, control, and monitoring of service-to-service communication within cloud-native applications. Buoyant's offerings aim to enhance the speed, security, and reliability of applications, supporting various hosting activities such as web hosting and application service provisioning. The company is well-funded and has garnered backing from prominent investors, striving to provide robust capabilities to organizations seeking to improve their application infrastructure.
Fletch is a data analytics platform that streamlines the process of data management and analysis for security teams. By employing advanced AI search technology, Fletch automatically connects and maintains various data feeds, allowing users—both technical and non-technical—to quickly access valuable insights. The platform organizes and cross-correlates data, offering visualizations and trends in an understandable format. Fletch focuses on providing ready-to-use analytics that help organizations gain visibility into their risk posture, compliance frameworks, and emerging threats. Users can select specific solution sets, connect their data sources, and within 24 hours, receive actionable insights to enhance operational efficiency. With a proven track record in delivering analytics solutions for Fortune 500 companies, small and medium enterprises, and government agencies, Fletch aims to eliminate busywork and empower users to make informed decisions swiftly. The company is supported by prominent investors, including August Capital and Google Ventures.
Element AI Inc. provides artificial intelligence solutions (AI) for organizations to identify opportunities to use artificial intelligence and machine learning and build AI solutions. It operates an AI as a Service (AIaaS) platform that enables businesses to launch and incubate AI solutions in partnership with large corporations. The company also operates a research and development laboratory that conducts research to deploy AI in computing infrastructure. It provides its products to insurance, banking and capital markets, manufacturing, logistics, retail, and consumer packaged goods industries. Element AI Inc. was founded in 2016 and is headquartered in Montreal, Canada with an additional office in Toronto, Canada.
Citrine Informatics, Inc. is a technology company that operates an artificial intelligence platform focused on materials development. Established in 2013 and headquartered in Redwood City, California, with an additional office in Pittsburgh, Pennsylvania, the company specializes in aggregating and analyzing extensive technical data related to materials, chemicals, and devices. Its platform leverages machine learning and data science to enhance research and development, manufacturing, and supply chain operations for organizations involved in physical product production. By facilitating the discovery of new materials and identifying defects early in the research process, Citrine Informatics aims to streamline product growth and design, thereby transforming the materials and chemicals development landscape.
Mythic Inc. is a technology company that specializes in designing and developing silicon chips and artificial intelligence (AI) processing units. Founded in 2012 and headquartered in Redwood City, California, with an office in Austin, Texas, Mythic focuses on creating analog matrix processors that enable AI capabilities across a range of devices, from fitness bands and hearing aids to self-driving cars and robotic drones. The company’s flagship products include the M1076 Analog Matrix Processor and various PCIe and M.2 cards. Mythic's technology integrates hybrid digital and analog computations within flash arrays, providing desktop-grade compute power in a compact form factor while maintaining performance, energy efficiency, and accuracy. The company has assembled a diverse team of experts in neural networks, software design, and processor architecture to advance AI deployment in real-world environments.
Aporeto, Inc. is a San Jose-based company that specializes in cloud-native security solutions tailored for deploying and operating applications in modern distributed systems, including those based on containers, microservices, and serverless architectures. Founded in 2015, Aporeto provides a comprehensive security platform that enables organizations to secure their workloads across various infrastructures—public, private, or hybrid—by leveraging identity-based access control to maintain a Zero Trust security posture. The company's offerings include the Aporeto Cloud Identity Framework, which facilitates consistent policy enforcement between enterprise applications and managed services. Aporeto's solutions are designed to protect cloud applications from potential attacks by ensuring that all communications are authenticated and authorized.
BitFusion.io Inc. specializes in optimizing computing performance through innovative software and hardware solutions. Founded in 2015 and based in Austin, Texas, the company provides tools that enhance the efficiency of existing clouds and data centers. Its offerings include Bitfusion software, which accelerates applications, and Bitfusion appliances that combine hardware accelerators with software libraries. Additionally, the Bitfusion Supercloud delivers on-demand access to hardware accelerators like FPGAs, facilitating rapid application acceleration. The company's solutions cater to various sectors, including computer vision, media encoding, scientific computing, bioinformatics, and search applications. BitFusion aims to simplify the AI application lifecycle by enabling organizations to cluster, share, scale, and manage computing resources effectively, thereby reducing costs and complexities. As of July 2019, BitFusion operates as a subsidiary of VMware, Inc.
Freenome, Inc., is an artificial intelligence (AI) genomics biotech company. The company develops and provides a medical arti?cial intelligence platform for early detection of cancer. It develops blood tests for early-cancer screening and treatment selection. The company also provides clinical research services. Freenome, Inc. was founded in 2014 and is based in South San Francisco, California.
Fauna, Inc. offers a cloud-based data application programming interface (API) designed for serverless applications, primarily through its product, FaunaDB. This NoSQL database combines a distributed transactional query engine with robust scalability and policy-based security features. FaunaDB provides a web-native GraphQL API that can be accessed from browsers, mobile clients, or serverless functions, while its serverless query language (FQL) enhances development by allowing complex queries that integrate various data types. The platform supports a wide array of programming languages and frameworks, including JavaScript, Python, and Ruby, facilitating seamless connections for developers. Fauna's database solutions emphasize unified capabilities across relational, temporal, and graph data, ensuring consistent performance and strong security measures. Founded in 2011 and headquartered in San Francisco, Fauna has garnered trust from notable clients like Nextdoor and NVIDIA and is supported by prominent venture capital investors.
Caption Health, Inc. develops artificial intelligence-based software solutions designed to assist healthcare providers in acquiring and interpreting ultrasound exams. The company's flagship product, Caption AI, offers real-time guidance for performing echocardiography, enabling practitioners to capture diagnostic-quality images, automate quality assessments, and interpret ultrasound results effectively. Founded in 2013 and headquartered in Brisbane, California, Caption Health was previously known as Bay Labs, Inc. The company focuses on enhancing the capabilities of ultrasound technology through innovative software, ultimately aiming to improve patient outcomes in medical imaging.
Mythic Inc. is a technology company that specializes in designing and developing silicon chips and artificial intelligence (AI) processing units. Founded in 2012 and headquartered in Redwood City, California, with an office in Austin, Texas, Mythic focuses on creating analog matrix processors that enable AI capabilities across a range of devices, from fitness bands and hearing aids to self-driving cars and robotic drones. The company’s flagship products include the M1076 Analog Matrix Processor and various PCIe and M.2 cards. Mythic's technology integrates hybrid digital and analog computations within flash arrays, providing desktop-grade compute power in a compact form factor while maintaining performance, energy efficiency, and accuracy. The company has assembled a diverse team of experts in neural networks, software design, and processor architecture to advance AI deployment in real-world environments.
Recursion Pharmaceuticals is a clinical-stage biotechnology company based in Salt Lake City, Utah, founded in 2013. The company utilizes artificial intelligence, automation, and experimental biology to streamline drug discovery and develop treatments for various diseases modeled at the cellular level. Its innovative platform includes multiple software solutions such as ReChem for chemical compound design, ReScreen for managing complex experiments, and RePredict, which employs machine learning to analyze drug compound relationships. Initially focused on drug repurposing for rare diseases, Recursion has expanded its research to address a wider range of conditions, including aging, inflammation, infectious diseases, and immunology. By leveraging advanced technology and high-throughput automated screening, Recursion Pharmaceuticals aims to create a comprehensive understanding of human cellular biology, significantly enhancing the efficiency and effectiveness of discovering new treatments.
Cape Analytics uses deep learning and geospatial imagery to provide instant property intelligence for buildings across the United States. Cape Analytics enables insurers and other property stakeholders to access valuable property attributes at time of underwriting—with the accuracy and detail that traditionally required an on-site inspection, but with the speed and coverage of property record pre-fill. Founded in 2014, Cape Analytics is backed by leading venture firms and comprised of computer vision and risk analysis experts.
Recursion Pharmaceuticals is a clinical-stage biotechnology company based in Salt Lake City, Utah, founded in 2013. The company utilizes artificial intelligence, automation, and experimental biology to streamline drug discovery and develop treatments for various diseases modeled at the cellular level. Its innovative platform includes multiple software solutions such as ReChem for chemical compound design, ReScreen for managing complex experiments, and RePredict, which employs machine learning to analyze drug compound relationships. Initially focused on drug repurposing for rare diseases, Recursion has expanded its research to address a wider range of conditions, including aging, inflammation, infectious diseases, and immunology. By leveraging advanced technology and high-throughput automated screening, Recursion Pharmaceuticals aims to create a comprehensive understanding of human cellular biology, significantly enhancing the efficiency and effectiveness of discovering new treatments.
BlueTalon is a provider of data-centric security for big data, data lakes, and new data initiatives. The company's Policy Engine delivers precise, consistent, and dynamic user access controls to data across Hadoop, Spark, Cassandra, and SQL-based data platforms. The BlueTalon Audit Engine provides a full audit trail at the level of detail required for compliance to regulations: user and data.
Fortune 100 have deployed BlueTalon to eliminate security blind spots and gain visibility and control at the data layer across cloud-based and on-premises environments. BlueTalon was named a 2016 Gartner cool vendor and won numerous security and big data awards.
SigOpt, Inc. operates an optimization platform designed to enhance model development across various applications, including web, mobile, machine learning, and physical experiments. Established in 2014 and based in San Francisco, California, SigOpt provides a REST API that seamlessly integrates into existing machine learning workflows. The platform employs a black-box optimization approach, allowing users to input parameter spaces and performance metrics without needing to share underlying training data. By continuously refining its models, SigOpt suggests optimal hyper-parameter configurations, thereby accelerating the development process and improving the reliability of results. In 2020, SigOpt became a subsidiary of Intel Corporation, further strengthening its position in the market.
Gladly Software, Inc. is a San Francisco-based company that specializes in cloud-based software designed for the contact center market, primarily serving B2C brands. Founded in 2014, Gladly provides a customer service platform that facilitates seamless communication between brands and their customers across various channels, including voice, email, messaging, chat, and social media. The platform focuses on fostering meaningful interactions, allowing agents to engage with customers in a way that prioritizes personal connection and builds long-term loyalty. By centering the customer experience, Gladly aims to enhance agent empowerment and create consistently positive experiences that resonate with users. The company is supported by notable investors, including Greylock Partners, GGV Capital, NEA, and JetBlue Ventures.
Gradle, Inc. is a developer of open-source build automation software that aims to transform the software development process. The Gradle Build Tool is widely recognized as the most popular build tool for open-source JVM projects, averaging over 19 million downloads monthly and being utilized by notable projects such as Spring Boot and JUnit. Gradle Enterprise complements this by providing a software build performance acceleration and analytics platform, designed to enhance productivity for software development teams. This self-hosted solution utilizes advanced acceleration technologies to reduce build times significantly and employs data analytics for efficient troubleshooting. Gradle Enterprise supports the discipline of Developer Productivity Engineering, enhancing the build and test processes within both Gradle and Maven environments. By unifying and automating build processes, Gradle, Inc. enables enterprises to improve their software delivery capabilities effectively.
Rescale, Inc. is a provider of cloud-based infrastructure and software platforms that facilitate scientific and engineering simulations. Founded in 2011 and headquartered in San Francisco, the company offers several products, including ScaleX Pro for independent professionals and small to medium-sized businesses, and ScaleX Developer, which allows external developers to build and deploy applications on Rescale's platform. Additionally, ScaleX Enterprise provides a comprehensive simulation solution that integrates on-premise high-performance computing resources and software management. Rescale serves various industries, including aerospace, automotive, consumer products, electronics, oil and gas, and life sciences, leveraging advanced technologies to empower engineers and scientists in their research and product development efforts. With a global presence that includes offices in Tokyo, Munich, and Singapore, Rescale continues to expand its role as a leading provider of cloud simulation services.
Agenovir Corporation is focused on the research and development of antiviral therapeutics aimed at addressing diseases related to latent or persistent viral reservoirs. Established in 2014 and based in South San Francisco, California, the company employs innovative nucleases, including CRISPR/Cas9 technology, to target and disrupt viral DNA. This approach allows for the creation of a new class of nucleic acid-based antiviral treatments that aim to eliminate pathogenic viral genomes. Agenovir's mission is to provide effective solutions for healthcare providers treating patients suffering from severe and chronic viral infections, ultimately advancing the field of antiviral therapeutics. As of January 31, 2019, Agenovir operates as a subsidiary of Vir Biotechnology, Inc.
Haven, Inc. operates a cloud-based logistics platform for trading companies. The company’s trade management software enables to take control of logistics, including automated procurement, documentation, tracking, and payments. Its platform automates freight and logistics for commodity traders, food producers, and consumer goods companies. The company was founded in 2014 and is headquartered in San Francisco, California. It has additional offices in Switzerland.
Kairos Aerospace provides large-scale, aerial monitoring of methane emissions. The company completed the first-ever basin-wide aerial survey for methane detection in its 2019 survey of the Permian Basin. Kairos Aerospace’s mission is to improve operational excellence for the oil and gas industry with cost-effective, efficient methane reductions at scale.
Verdigris Technologies, Inc. specializes in developing software solutions for electricity monitoring and management in commercial facilities. The company's primary product, Verdigris Energy Tracker, identifies operational inefficiencies, automates building management, and predicts demand peaks while detecting equipment failures. By utilizing wireless hardware, Verdigris collects and transmits electricity consumption data to the cloud, enhancing energy efficiency and facilitating smarter facility operations. Additionally, the company's Building.AI platform offers advanced analytics for enterprise facility managers, enabling real-time monitoring and optimization of power usage at the device level. This machine learning-based software provides critical insights that help organizations improve operational performance and reduce energy costs. Founded in 2010, Verdigris Technologies is headquartered in Moffett Field, California.
Pivot Bio is a biotechnology company founded in 2010 and based in Emeryville, California, that focuses on enhancing crop nutrition through the use of engineered microbes. The company leverages its deep understanding of the plant microbiome, employing engineering principles and data science to map microbial dynamics and develop beneficial traits. Pivot Bio's proprietary ON Technology utilizes naturally occurring microbes to provide crops with essential nutrients, particularly nitrogen, which is crucial for growth. This innovative approach aims to replace synthetic nitrogen fertilizers, thereby reducing the environmental impact associated with conventional farming practices. By enhancing crops' ability to capture and metabolize atmospheric nitrogen, Pivot Bio seeks to lower farming costs, improve crop yields, and contribute to a sustainable agricultural future that benefits both the planet and food supply.
Capella Bioscience Limited is involved in the discovery and development of monoclonal antibodies (mAbs) for therapeutic applications. The company utilizes proprietary technologies to create and commercialize mAb-based medicines targeting oncology, autoimmune diseases, and other conditions. Founded in 2014 and headquartered in London, the firm operates both independently and in collaboration with biotechnology firms and academic institutions to advance its research and development efforts. Through its innovative approach, Capella Bioscience aims to contribute to the development of advanced medical therapies that address significant health challenges.